Dr. Xinxin Cao 曹欣欣
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of hematologic malignancies, including lymphomas, plasma cell disorders (multiple myeloma, Waldenström macroglobulinemia, light-chain amyloidosis, MGUS), and histiocytic neoplasms (Erdheim-Chester disease, Langerhans cell histiocytosis, Rosai-Dorfman disease).
Dr. Cao earned a medical degree from Peking Union Medical College in 2005. After serving as a resident and chief resident at Peking Union Medical College Hospital, Dr. Cao became an attending physician in hematology in 2009, associate chief physician in 2016, and chief physician in 2022. In December 2024, Dr. Cao joined the Cancer Hospital, Chinese Academy of Medical Sciences.
Professional roles
- Member, Chinese Medical Association
- Youth Committee Member, Hematology Branch, Chinese Medical Association
- Member, Histiocytosis Branch, Chinese Medical Doctor Association
- Youth Committee Member, Hematologic Tumor Branch, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Cao Xinxin). Papers usually list the name as Xinxin Cao or Cao X.
Selected publications
20 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Case Report: Erdheim-Chester disease with liver involvement successfully treated with trametinib. PubMed 42294265
- Mol Cancer, 2026 (senior author): CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies. PubMed 41882710
- Orphanet J Rare Dis, 2026 (senior author): Clinical characteristics, genomic profiling, treatments, and outcomes of Langerhans cell sarcoma. PubMed 41559709
- Int J Hematol, 2025 (senior author): Langerhans cell histiocytosis with mesenteric involvement successfully treated with trametinib: a rare cause of small intestine obstruction. PubMed 40976809
- Ann Hematol, 2025 (senior author): Efficacy and safety of Dabrafenib in Erdheim-Chester disease. PubMed 41207925
- EClinicalMedicine, 2025 (first author): Luvometinib in patients with Langerhans cell histiocytosis, Erdheim-Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study. PubMed 41035796
- Leuk Lymphoma, 2025 (senior author): Evidence of the modified staging system and comparative performance of IPSS and revised IPSS in a Single-Center Asian cohort with Waldenström macroglobulinemia. PubMed 40382792
- Innovation (Camb), 2025 (senior author): Diagnosis and treatment of Langerhans cell histiocytosis in adults. PubMed 40979301
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion